ⓘ Lulizumab pegol

                                     

ⓘ Lulizumab pegol

Lulizumab pegol is a monoclonal antibody designed for the treatment of autoimmune diseases.

This drug developed by Bristol-Myers Squibb.

                                     
  • half - life of the drug. Examples include: Alacizumab pegol Calaspargase pegol Certolizumab pegol Lulizumab pegol Swierczewska, Magdalena Lee, Kang Choon Lee
  • phase III Fostemsavir BMS - 663068 phase III Lirilumab BMS - 986015 Lulizumab pegol BMS - 931699 phase II List of biotech and pharmaceutical companies
  • CD40 multiple myeloma, non - Hodgkin s lymphoma, Hodgkin s lymphoma Lulizumab pegol mab humanized CD28 autoimmune diseases Lumiliximab mab chimeric CD23